Daiichi Sankyo Inc., part of Daiichi Sankyo Co. Ltd., of Tokyo, appointed Antoine Yver global head, oncology research and development. Yver will have responsibility for leading all of the global research and development across the oncology therapeutic area including external investments, internal pipeline decisions and resourcing requirements. Read More

HONG KONG – A recent scandal involving the illegal sales of vaccines has further eroded the trust of the Chinese public, particularly parents, toward drug safety and the government's loophole-ridden supervision of the space. Read More

TOKYO – News that Japanese pharma Daiichi Sankyo Group is pinning its growth strategy on oncology followed on the heels of the announcement that Daiichi and partner, U.S. firm Arqule Inc., are advancing their METIV-HCC study for tivantinib after achieving 60 percent of the target number of 500 patients with MET-high tumors in December. Read More

HONG KONG — Japanese scientists from the Riken Center for Developmental Biology (CDB) have for the first time successfully grown complex skin tissue complete with hair follicles and oil-secreting sebaceous glands using reprogrammed induced pluripotent stem (iPS) cells. They then transplanted it into living mice, paving the way for growing functional skin grafts for use in regenerative medicine. Read More

TOKYO – Japanese company Fujifilm Corp., best known for its photographic equipment, is adapting its technology for use in human regenerative therapy. Read More

SHANGHAI – In China, meeting the country's unmet medical needs is a frequent topic of discussion. For biopharmas, that can mean filling the substantial gap between which drugs are available in developed markets and which are available for patients here. Read More

SHANGHAI – While there may be choppy waters all around – growth slowing in China and public markets no longer guaranteeing a safe haven for high valuation exits – China's health care industry is still thought to be a solid bet for investors, according to sentiment from the 7th China Healthcare Investment Conference. Read More

HONG KONG – South Korea's oldest and most respected pharmaceutical company, Yuhan Co. Ltd., is looking to move more aggressively into the global biopharma scene by striking up partnerships with U.S.-based companies that have larger global presences. Read More

HONG KONG – South Korea's Samsung Bioepis Co. Ltd. has taken another step forward in its push to market biosimilars globally having received positive feedback from the EMA for its biosimilar to Remicade (infliximab, Janssen Biotech Inc.). The company is now expecting an approval soon. Read More